Please assess the completion status of the following clinical trial:

Trial Title: PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with chronic hepatitis B:~  * Serum hepatitis B surface antigen positive for at least 6 months~ * Serum hepatitis B e antigen positive~ * Serum negative for hepatitis B surface and e antibodies~ * Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000 IU/mL~ * Alanine aminotransferase (ALT) 2- to 10-times the upper limit of normal~* Compensated liver disease with certain minimum hematological and serum biochemical criteria~Exclusion Criteria:~* Significant hepatic disease from an etiology other than hepatitis B virus~* Antiviral treatment for hepatitis within previous 6 months~* History of severe psychiatric disease, especially depression~* Unstable or significant cardiovascular disease~* Prolonged exposure to known hepatotoxins such as alcohol or drugs~* Any condition that could interfere with the subject participating in and completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PEG 1.0 mcg/kg weekly (QW) * 24 weeks (Type: ACTIVE_COMPARATOR): PegIntron 1.0 mcg/kg weekly (QW) \* 24 weeks + 24 weeks follow-up
- PEG 1.5 mcg/kg QW * 24 wks (Type: EXPERIMENTAL): PegIntron 1.5 mcg/kg QW \* 24 wks + 24 wks follow-up
- PEG 1.5 mcg/kg QW * 48 wks (Type: EXPERIMENTAL): PegIntron 1.5 mcg/kg QW \* 48 wks + 24 wks follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).